Treatment efficacy end-points in the studies reviewed
| First author [Ref.] | Time to conversion | Treatment success | Failure | Death | Follow-up months | ||||||||
| MDR | XDR | MDR | XDR | MDR | XDR | p-value | RR | MDR | XDR | p-value | RR | ||
| Gandhi 9 | 52 (98) | ||||||||||||
| Migliori 10 | SS: 41 days#C: 58 days# | SS: 110 days#C: 97.5 days# | 45 (35.7) | 0 | 8 (6.3) | 4 (36.4) | <0.001 | 5.45 | 42# | ||||
| Migliori 11 | SS: 56 days#C: 60 days# | SS: 110 days#C: 168 days# | 165 (45.7) | 22 (34.4) | 32 (8.9) | 12 (18.7) | 0.016 | 2.12 | 43 (11.9) | 14 (21.9) | 0.03 | 1.84 | 42# |
| Kim 12 | 109 (64.9) | 23 (53.5) | 29 (17.3) | 11 (25.6) | 0.21 | 1.48 | 13 (7.7) | 6 (14.0) | 0.20 | 1.8 | XDR: 43#MDR: 25# | ||
| Mitnick 16 | C: 61 days# | C: 90 days# | 400 (66.3) | 29 (60.4) | 13 (2.1) | 5 (10.4) | 0.7 | 0.83 | 123 (20.4) | 11 (22.9) | 0.67 | 1.12 | 19.4# |
| Chan 17 | 23.4¶ | 2.5+ | 0.07 | ||||||||||
| Keshavjee 19 | C: 2 months# | C: 2 months# | 386 (66.7) | 14 (48.3) | 49 (8) | 9 (31) | 0.00005 | 3.67 | 29 (5) | 2 (7) | 0.65 | 1.38 | |
| Eker 18 | SS: 53.5 days#C: 61.5 days# | SS: 88 days#C: 117 days# | 105 (59.3) | 4 (57.1) | 1 (0.6) | 0 | 14 (7.9) | 1 (14.3) | 0.5 | 1.81 | 48# | ||
| Kwon 20 | 84 (66) | 18 (67) | 24# | ||||||||||
| Lai 21 | |||||||||||||
| Banerjee 22 | C: 98.5 days# | C: 195 days# | 345 (66) | 7 (41.2) | 80 (15.3) | 5 (29.4) | 0.4 | 1.41 | |||||
| Bonilla 23 | C: 3 months# | C: 26 months# | 372 (75)§ | 18 (49)§ | 50 (10)§ | 5 (14)§ | 0.5 | 1.34 | 39 (8)§ | 8 (22)§ | 0.005 | 2.74 | |
| Kim 24 | 615 (46.2) | 22 (29.3) | 53 (4) | 12 (16) | 124 (9.3) | 20 (26.7) | 36–84ƒ | ||||||
| Median | SS: 53.5 daysC: 61 days | SS: 110 daysC: 117 days | 42 | ||||||||||
Data are presented as n (%), unless otherwise stated. MDR: multidrug-resistant; XDR: extensively drug-resistant; RR: relative risk; SS: sputum smear; C: culture. #: median; ¶: odds ratio; +: hazard ratio; §: individualised treatment regimen; ƒ: range.